UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): August 18, 2017
 
MetaStat, Inc.
(Exact name of registrant as specified in its charter)
 
Nevada
(State or other jurisdiction of incorporation)
 
  000-52735
  20-8753132
  (Commission File Number)
  (IRS Employer Identification No.)
                                                                                                                                                                                       
27 Drydock Avenue, 2 nd Floor
Boston, MA 02210
(Address of principal executive offices and zip code)
 
(617) 531-6500
(Registrant's telephone number including area code)
 
 
(Registrant's former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
 
[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[  ] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
 
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 
Item 8.01.  Entry into a Material Definitive Agreement.
 
On August 18, 2017, MetaStat, Inc. (“ MetaStat ”) received payment of $146,022 from Celgene Corporation (“ Celgene ”) for satisfactory completion of the third of four milestones pursuant to the pilot materials transfer agreement, as amended (the “ Research Agreement ”) between the parties.
 
MetaStat has successfully completed testing of Celgene’s proprietary materials in its nonclinical cell line models and is currently testing in its nonclinical animal models. Additionally, the term of the Research Agreement was extended by the parties through December 22, 2017. To date, MetaStat has received an aggregate of $876,134 from Celgene pursuant to the Research Agreement.
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 


 
 
 
Dated: August 22, 2017
 
 
METASTAT, INC.  
 
By: /s/ Douglas A. Hamilton
       Name: Douglas A. Hamilton        
       Title: President and CEO
 
 
 
 
 
MetaStat (CE) (USOTC:MTST)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse MetaStat (CE)
MetaStat (CE) (USOTC:MTST)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse MetaStat (CE)